- Poster presentation
- Open Access
A novel DDAH-1 inhibitor improved cardiovascular function in a short-term anesthetized rat model of sepsis
Critical Care volume 15, Article number: P30 (2011)
Excessive NOS activity and NO overproduction are believed to play an important role in sepsis-induced macrocirculatory and microcirculatory dysfunction. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthesis, is extensively metabolised by dimethylarginine dimethylaminohydrolase (DDAH). The DDAH-1 isoform is present in vascular smooth muscle so its inhibition should theoretically reverse sepsis-induced hypotension. We thus investigated the dose-dependent cardiovascular effects of a novel DDAH-1 competitive inhibitor, L-257, in experimental sepsis.
Anaesthetised, spontaneously breathing male Wistar rats (body weight 270 to 330 g) had their left carotid artery and right internal jugular vein cannulated for arterial pressure monitoring and fluid infusion, respectively. Then 40 mg/kg Klebsiella pneumoniae lipopolysaccharide was administered intravenously over 30 minutes followed by fluid resuscitation at a rate of 10 ml/kg/hour thereafter. When the mean arterial pressure fell over 20% below baseline, groups (n = 6) were randomized to receive a bolus dose of L-257 of 0 (control), 3, 30 or 300 mg/kg. Animals were sacrificed 2 hours later with prior measurement of gastrocnemius muscle microcirculatory perfusion and with collection of plasma samples for biochemistry, arginine, ADMA and nitrate/nitrite measurements.
The bolus doses of L-257 were given after approximately 60 to 90 minutes post endotoxin when the mean BP fell over 20%. Arterial pressure, perfused capillary density and microcirculatory flow index were better maintained than in controls, especially at higher doses (Figure 1, P < 0.05). Significantly higher plasma ADMA concentrations and ADMA/arginine ratios were seen in the 30 mg/kg bolus group (Figure 2, P < 0.05). Plasma nitrate/nitrite levels in the treated animals were significantly lower compared with those in controls (Figure 2, P < 0.05).
In this short-term rat model of endotoxaemia, we demonstrated protective dose-dependent effects of a novel DDAH-1 inhibitor, L-257, on cardiovascular function. This was associated with an elevation of plasma ADMA level and a resultant reduction of plasma nitrate/nitrite level.
This study was funded by Wellcome Trust in the UK.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Wang, Z., Taylor, V., Stidwill, R. et al. A novel DDAH-1 inhibitor improved cardiovascular function in a short-term anesthetized rat model of sepsis. Crit Care 15 (Suppl 3), P30 (2011). https://doi.org/10.1186/cc10399
- ADMA Level
- Asymmetric Dimethylarginine
- Plasma ADMA
- ADMA Concentration